A key subject on everyones mind at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, was immuno-oncology (IO): predictive testing, combinations, trials, new targets; the list goes on. Speaking from the meeting, Keith Kerr, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, gave us his thoughts on this exciting topic. Dr Kerr highlighted a number of interesting questions, including whether IO is for all patients or not, the affordability of regimens, and if clinicians should use all agents in the first-line setting.
Immuno-oncology focus: questions to be answered
